Hims & Hers Health Inc. shares rose about 3.9% after announcing generic semaglutide availability in Canada.
The company will offer personalised treatment plans starting at CAD 149 per month, including medication, care‑team support, nutrition and lifestyle guidance.
Generic semaglutide is approved for Type 2 diabetes and may be prescribed for weight management, reducing cost barriers for thirds of overweight Canadians.
Dr. Sandy Van and GM Austin Kouri highlighted the launch as expanding access with lower costs and comprehensive Canadian‑based care.